

**ENCLOSURES (check all that apply)**

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Reply to Missing Parts/ Incomplete Application

☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD

☐ After Allowance Communication to TC

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify below):  
Form HDP-1449  
Return Receipt Postcard


Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm

Harness, Dickey & Pierce, P.L.C.

Signature



Printed Name

David M. Gryte

Date

February 2, 2005

Reg. No.

41,809

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Typed or printed name

David M. Gryte

Express Mail Label No.

EV 327050953 US

Signature



Date

February 2, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

327050953



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Joseph J. McDonald, et al.  
Serial No: 10/700,202  
Filed: November 3, 2003  
For: Piperidinyl- and Piperazinyl- Sulfonylmethyl Hydroxamic Acids and  
Their Use as Protease Inhibitors  
Confirmation No: 5566  
Art Unit: 1624  
Examiner: TBA  
Attorney Ref: 00988/4/US  
Pfizer Ref: 27378/USA  
HDP Ref: 6794-000053/CPB

February 2, 2005

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration and that the Examiner cite each document of record in the prosecution history of the present application by initialing Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a listed document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent

search consistent with 37 CFR §1.104 and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

The references cited in this information disclosure statement have been submitted to the Office in the parent application (Barta et al., Appl. No. 10/618,288 (filed April 25, 2003)). Copies of the references are therefore not being provided in accordance with 37 C.F.R. §1.98(d) and MPEP §609 Part III(A)(2). Applicants, however, will provide copies of such references upon request from the Examiner.

Applicants presume that the Examiner has access to the file history for the parent patent application. Applicants further presume that the Examiner is aware of the issues raised and the scope of claims in that case, and will take them into account when examining this patent application. Upon request from the Examiner, Applicants can provide copies of the substantive Office actions or any other information relating to those cases, to the extent Applicants have such information in their possession.

Applicants make no representation as to the accuracy of any translation that has been submitted in the parent application.


Applicants request early and favorable consideration of this patent application.

\* \* \* \* \*

Applicants believe that they do not owe any fee in connection with this Information Disclosure Statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Information Disclosure Statement  
Appl. No. 10/700,202  
February 2, 2005


Respectfully submitted,



David M. Gryte, PTO Reg. No. 41,809  
Harness, Dickey & Pierce  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500 (tel)  
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **February 2, 2005** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.



DMG/JPG/PML



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Sheet 1 of 6

ATTORNEY DOCKET NO.

00988/4/US (Pfizer Ref.  
27378/USA)

SERIAL NO.

10/700,202

APPLICANT

Joseph J. McDonald, et al.

FILING DATE

November 3, 2003

GROUP

1624

## U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.		4,595,700	6/17/1986	Donald, et al.	514/616	
2.		5,451,676	9/19/1995	Whittaker, et al.	546/118	
3.		5,472,978	12/5/1995	Baker, et al.	514/443	
4.		5,475,138	12/12/1995	Pal, et al.	564/342	
5.		5,599,994	2/4/1997	Pal, et al.	564/355	
6.		5,932,595	8/3/1999	Bender, et al.	514/317	
7.		5,998,412	12/7/1999	Broka, et al.	514/250	
8.		6,013,649	1/11/2000	Freskos, et al.	514/237.8	
9.		6,300,514	10/09/2001	Takahashi, et al.	560/17	
10.		6,372,758, including 9/5/01 Office action and 10/25/01 notice of allowance	4/16/2002	DeCrescenzo, et al.	514/316	
11.		6,387,931 (withdrawn)	5/14/2002	Dack, et al.	514/318	
12.		6,448,250, including 9/5/01 Office action and 1/29/02 notice of allowance	9/10/2002	DeCrescenzo, et al.	514/252	
13.		6,492,367, including 7/5/02 notice of allowance	12/10/2002	DeCrescenzo, et al.	514/252	
14.		6,495,568	12/17/2002	Dack, et al.	514/318	
15.		6,683,078	1/27/2004	Barta, et al.	514/231.5	07/12/2002
16.		6,683,093	1/27/2004	Barta, et al.	514/316	11/21/2001
17.		6,689,794	2/10/2004	Freskos, et al.	514/318	05/10/2002

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 327050953 US

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)</p> <p>Sheet 2 of 6</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
	APPLICANT	
	Joseph J. McDonald, et al.	
	FILING DATE	GROUP
	November 3, 2003	1624

18.		6,800,646, including 12/19/02 and 7/22/03 Office actions, and 11/21/03 notice of allowance	10/5/2004	DeCrescenzo, et al.	514/316	09/30/2002
19.		Appl. No. 09/311,837		Barta, et al.		05/14/1999
20.		Publ. No. 2004-0024024 A1 (Appl. No. 10/291,983)		Freskos, et al.	514/326	11/12/2002
21.		Appl. No. 10/887,450, including pending claims (as of January 31, 2005) and 12/2/04 Office action		Boehm, et al.		07/08/2004

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
22.		EP 0 266 182	5/4/1988	Europe	C07D 307/32		
23.		EP 0 336 354	10/11/1989	Europe	C07D 239/42		X
24.		EP 0 606 046	7/13/1994	Europe	C07D 213/42		
25.		EP 0 780 386	6/25/1997	Europe	C07D 309/08		
26.		EP 0 930 067	7/21/1999	Europe	A61K 31/40		
27.		EP 0 931 788	7/28/1999	Europe	C07C 311/03		
28.		EP 1 081 137	3/7/2001	Europe	C07D 211/96		
29.		GB 1,067,965	5/10/1967	Great Britain	C07D 499/00		
30.		GB 2,263,109	7/14/1993	Great Britain	C07D 409/04		
31.		JP 4-338331	11/25/1992	Japan	A61K 31/365	partial	

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)</p> <p>Sheet 3 of 6</p>	ATTORNEY DOCKET NO.		SERIAL NO.
	00988/4/US (Pfizer Ref. 27378/USA)		10/700,202
	APPLICANT		
	Joseph J. McDonald, et al.		
	FILING DATE		GROUP
	November 3, 2003		1624

32.		WO 90/05719	5/31/1990	PCT	C07C 323/62		
33.		WO 93/20047	10/14/1993	PCT	C07C 317/44		
34.		WO 94/02466	2/3/1994	PCT	C07D 221/14		
35.		WO 94/24140	10/27/1994	PCT	C07H 13/04		
36.		WO 95/04720	2/16/1995	PCT	C07D 209/42		
37.		WO 95/09841	4/13/1995	PCT	C07C 323/60		
38.		WO 95/13064	5/18/1995	PCT	A61K 31/415		
39.		WO 95/13289	5/18/1995	PCT	C07K 5/062		
40.		WO 95/29892	11/9/1995	PCT	C07D 207/327		
41.		WO 96/06074	2/29/1996	PCT	C07C 259/06		
42.		WO 96/11209	4/18/1996	PCT	C07K 5/06		
43.		WO 97/05865	2/20/1997	PCT	A61K 31/215		
44.		WO 97/20824	6/12/1997	PCT	C07D 241/04		
45.		WO 97/24117	7/10/1997	PCT	A61K 31/19		
46.		WO 97/48368	12/24/1997	PCT	A61K		
47.		WO 98/37877	9/3/1998	PCT	A61K 31/16		
48.		WO 98/38163	9/3/1998	PCT	C07C 323/60		
49.		WO 98/38859	9/11/1998	PCT	A01N 37/28		
50.		WO 98/39329	9/11/1998	PCT	C07D 413/12		
51.		WO 99/09000	2/25/1999	PCT	C07C 235/00		

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)</p> <p>Sheet 4 of 6</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
	APPLICANT	
	Joseph J. McDonald, et al.	
	FILING DATE	GROUP
	November 3, 2003	1624

52.		WO 99/24399	5/20/1999	PCT	C07C 311/04		
53.		WO 99/25687	5/27/1999	PCT	C07D 211/66		
54.		WO 99/29667	6/17/1999	PCT	C07D 211/16		
55.		WO 99/42436	8/26/1999	PCT	C07C 239/14		
56.		WO 00/38717	6/7/2000	PCT	A61K 41/00		
57.		WO 00/46221	8/10/2000	PCT	C07D 405/12		
58.		WO 00/50396	8/31/2000	PCT	C07D 211/66		
59.		WO 00/59874	10/12/2002	PCT	C07C 259/06		
60.		WO 00/69819	11/23/2002	PCT	C07D 211/16		
61.		WO 00/69821	11/23/2000	PCT	C07D 211/66		
62.		WO 00/74681	12/14/2000	PCT	A61K 31/451		
63.		WO 02/092588	11/21/2002	PCT	C07D 309/08		
64.		WO 03/007930	1/30/2003	PCT	A61K 31/166		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
65.		Brown, P.D., "Synthetic Inhibitors of Matrix Metalloproteinases," in <i>Matrix Metalloproteinases</i> , pp. 243-61 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).
66.		Dack, et al., "Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors," CA 131:44740 (1999) [CA Plus Accession No. 1999:388166].
67.		Denis et al., <i>Matrix metalloproteinase inhibitors: Present achievements and future prospects</i> , INVEST. NEW DRUGS, 15:175-185 (1997).

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 5 of 6</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
	APPLICANT	
	Joseph J. McDonald, et al.	
	FILING DATE	GROUP
	November 3, 2003	1624

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
68.		Freije et al., <i>Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas</i> , J BIOL. CHEM., 269(24):16766-16773 (1994).
69.		Gearing et al., <i>Processing of tumour necrosis factor-<math>\alpha</math> precursor by metalloproteinases</i> , NATURE, 370:555-557 (1994).
70.		Gu et al., <i>S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death</i> , SCIENCE, 297:1186-90 (2002).
71.		Hughes, et al., <i>Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro</i> ," BIOCHEM. J., 305:799-804 (1995).
72.		10/9/2003 Search Report and 8/3/2004 Preliminary Examination Report for International Application No. PCT/US03/13123
73.		Kenyon et al., <i>A model of angiogenesis in the mouse cornea</i> , INVEST. OPHTHALMOL. VIS. SCI., 37(8):1625-1632 (1996).
74.		Knight et al., <i>A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases</i> , FEBS LETT., 296(3):263-266 (1992).
75.		Kuzmic et al., <i>High-throughput enzyme kinetics: Simultaneous determination of tight-binding inhibition constants and enzyme concentration</i> , ANAL. BIOCHEM., 286(1):45-50 (2000).
76.		Luckow et al., <i>Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherihia coli</i> , J. VIROL., 67:4566-4579 (1993).
77.		Luckow, et al., "Insect Cell Expression Technology," in <i>Protein Engineering: Principles and Practice</i> , pp. 183-218 (John Wiley & Sons, Inc., New York, NY, Edited by J.L. Cleland et al., 1996)
78.		McClure, et al., "Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases," CA 131:125454 (1999) [CA Plus Accession No. 1999:468334].
79.		McGeehan et al., <i>Regulation of tumour necrosis factor-<math>\alpha</math> processing by a metalloproteinase inhibitor</i> , NATURE, 370:558-561 (1994).
80.		Mitchell et al., <i>Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage</i> , J. CLIN. INVEST. 97(3):761-768 (1996).
81.		Rasmussen et al., <i>Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat</i> , PHARMACOL. THER., 75(1):69-75 (1997).

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)</p> <p>Sheet 6 of 6</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
	APPLICANT	
	Joseph J. McDonald, et al.	
	FILING DATE	GROUP
	November 3, 2003	1624

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
82.		Reboul et al., <i>The new collagenase, collagenease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes</i> , J. CLIN. INVEST., 97(9):2011-2019 (1996).
83.		Schwartz et al., <i>Synthetic inhibitors of bacterial and mammalian interstitial collagenases</i> , PROG. IN MED. CHEM., 29:271-334 (1992).
84.		Tang, B. L., <i>ADAMTS: A Novel Family of Extracellular Matrix Proteases</i> , INT. J. BIOCHEM. CELL BIO., 33(11):33-44 (2001).
85.		Woessner, J.F., "The Matrix Metalloprotease Family" in <i>Matrix Metalloproteinases</i> , pp.1-14 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.